POORLY DIFFERENTIATED THYROID CARCINOMA

This adverse event was reported 10 times

These drugs are most commonly taken by patients reporting POORLY DIFFERENTIATED THYROID CARCINOMA:

# Drug Count
0 SORAFENIB 6
1 DENOSUMAB 2
2 LENVATINIB 2
3 PACLITAXEL 2
4 PACLITAXEL (AIBUMIN-BOUND) 2
5 PAZOPANIB 2
6 PAZOPANIB HYDROCHLORIDE 2
7 PEMBROLIZUMAB 2
8 PEMETREXED 2
9 PEMETREXED DISODIUM 2
See all common drugs associated with POORLY DIFFERENTIATED THYROID CARCINOMA

POORLY DIFFERENTIATED THYROID CARCINOMA is most prevalent among patients taking these drugs:

# Drug Count Frequency
0 CERITINIB 1 0.0004
1 SORAFENIB 6 0.0003
2 FREMANEZUMAB-VFRM 1 0.0001
3 PAZOPANIB HYDROCHLORIDE 2 0.0001
4 LENVATINIB 2 0.0001
5 LITHIUM CARBONATE 1 0.0001
6 PEMETREXED DISODIUM 2 0.0001
7 PACLITAXEL 2 0.0000
8 PEMBROLIZUMAB 2 0.0000
9 EMPAGLIFLOZIN 1 0.0000
See all drugs enriched for association with POORLY DIFFERENTIATED THYROID CARCINOMA